Table of Contents 2
List of Tables 5
List of Figures 5
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 27
Clinical Trials by Phase 29
In Progress Trials by Phase 30
Clinical Trials by Trial Status 31
Clinical Trials by End Point Status 33
Subjects Recruited Over a Period of Time 34
Clinical Trials by Sponsor Type 35
Prominent Sponsors 36
Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 42
Feb 23, 2017: Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 42
Feb 23, 2017: Children’s National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 43
Feb 17, 2017: Immune Pharmaceuticals Announces the launch of REMAIN, an international Overall Survival study with Ceplene and low dose Proleukin in REmission MAINtenance in Acute Myeloid Leukemia 43
Feb 13, 2017: Actinium Pharmaceuticals Presents Data On Actimab-A At BIO CEO & Investor Conference 44
Feb 06, 2017: FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. 44
Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 44
Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 45
Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 45
Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 46
Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 46
Jan 05, 2017: Mirati Therapeutics Provides Update On Cancer Pre-Clinical Program 47
Jan 03, 2017: Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN 47
Dec 28, 2016: argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine 48
Dec 27, 2016: Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A) 48
Dec 23, 2016: Anti-AXL Biologic Increases Tumor Sensitivity to Radiation and Check-Point Inhibitors 49
Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 49
Dec 15, 2016: Cellectis Announces Recombinant DNA Advisory Committee's (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN 50
Dec 07, 2016: Personalized Cancer Vaccine is Associated With Promising Outcomes for Patients with Acute Myeloid Leukemia 50
Dec 06, 2016: Oncternal Therapeutics Presented Data on TK216 at American Society of Hematology Meeting 51
Dec 06, 2016: Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH 51
Dec 06, 2016: Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology 52
Dec 06, 2016: Immunotherapy shows promise in preventing leukemia relapse 52
Dec 06, 2016: Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting 53
Dec 05, 2016: Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies 53
Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting 54
Dec 05, 2016: Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting 56
Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology 57
Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016 57
Dec 05, 2016: Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting 58
Dec 05, 2016: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting 59
Dec 05, 2016: BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016 60
Dec 05, 2016: Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting 61
Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 61
Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 62
Dec 05, 2016: Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting 63
Dec 05, 2016: Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 63
Dec 05, 2016: Cornerstone Pharmaceuticals Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin Lymphoma (T-cell NHL) at ASH 2016 64
Dec 05, 2016: ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting 65
Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting 66
Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 67
Dec 03, 2016: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 67
Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting 68
Dec 02, 2016: Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting 69
Dec 02, 2016: Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend 69
Dec 01, 2016: ERYTECH Presents New Data on GRASPAs Mechanism of Action at ASH Annual Meeting 70
Dec 01, 2016: argenx to provide update on ARGX-110 during American Society of Hematology Annual Meeting 71
Nov 29, 2016: New Research Validates both Single Agent and Synergistic Anticancer Activity for Aravive Biologics’ Anti-AXL Candidate in Multiple Tumor Types 72
Nov 29, 2016: Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials 72
Nov 29, 2016: Astex to Showcase Its Next-Generation Hypomethylating Agent Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 73
Clinical Trial Profile Snapshots 74
Appendix 1882
Abbreviations 1882
Definitions 1882
Research Methodology 1884
Secondary Research 1885
About GlobalData 1886
Contact Us 1886
Disclaimer 1886
Source 1887
